Maravai LifeSciences Holdings, Inc.

Good afternoon and thank you for standing by. At this time, I would like to welcome everyone to the Q4 2023 Miravai Life Sciences Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question again, please press the star one. I would now like to turn the conference over to Deb Hart, Head of Investors Relations.

Please go ahead. Good afternoon, everyone.

Thanks for joining us for our fourth quarter and year-end 2023 earnings call. Our press release and the slides that accompany today's call are posted on our website. and are available at investors.maravai.com. As you can see on our agenda for today on slide two, Trey will first provide you with a business update, and Kevin will review our financial results and guidance. Drew Burch, President of Nucleic Acid Production, will join the call for the question and answer session following our prepared remarks. We remind you that management will make forward-looking statements and refer to GAAP and non-GAAP financial measures during today's call. It is possible that actual results could differ from management's expectations. We refer you to slide three for more detail on forward-looking statements and our use of non-GAAP financial measures. Our just-issued press release provides reconciliations to the most directly comparable GAAP measures. Please also refer to Maravai's SEC filings for additional information on the risks and uncertainties that may impact our operating results, performance, and financial condition. Now I'll turn the call over to Trey.